Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans

PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions
Safety, Immunogenicity
Interventions
BIOLOGICAL

2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old

freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old

freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old

freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old

freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old

freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval

BIOLOGICAL

2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old

freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval

Sponsors
All Listed Sponsors
collaborator

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY

lead

Beijing Center for Disease Control and Prevention

OTHER_GOV